pharma · Breast Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · ALXO
ALX ONCOLOGY HOLDINGS
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS is a pharma organization headquartered in San Antonio, USA. It trades on NYSE under ticker ALXO. Primary therapeutic focus areas include Breast Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), A
Company details
- Status
- Public
- HQ
- 4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US
- Founded
- 2015
- Employees
- 2
- Programs
- 13
- Drugs
- 16
- Patents
- 0
AZACITIDINE
Phase 2 · small molecule · Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease
AZACITIDINE for Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease is a Phase 2 program (small_molecule) at ALX ONCOLOGY HOLDINGS INC with 1 ClinicalTrials.gov record(s).
Internal code AT148002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ALX ONCOLOGY HOLDINGS INC
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease
- Status
- active
- Trials
- 1